Twin Focus Capital Partners, LLC Vertex Pharmaceuticals Inc Transaction History

Twin Focus Capital Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $5,476 - $6,110	-20 Reduced 1.75%	1,122 $325,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $5,169 - $6,436	-22 Reduced 1.89%	1,142 $322,000
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $7,528 - $8,872	-34 Reduced 2.84%	1,164 $304,000
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $16,461 - $20,780	93 Added 8.42%	1,198 $263,000
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $1,269 - $1,420	7 Added 0.64%	1,105 $200,000
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $4,874 - $5,748	26 Added 2.43%	1,098 $221,000
Q1 2021 May 12, 2021	BUY	$207.02 - $241.31 $10,765 - $12,548	52 Added 5.1%	1,072 $230,000
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $8,280 - $11,043	40 Added 4.08%	1,020 $241,000
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $6,902 - $8,183	27 Added 2.83%	980 $267,000
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $225 - $295	-1 Reduced 0.1%	953 $277,000
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $3,595 - $4,460	18 Added 1.92%	954 $227,000
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $156,040 - $209,579	936 New	936 $205,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Twin Focus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Twin Focus Capital Partners, LLC with notifications on news.